Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in the fast-growing obesity drug market.
Wegovy sales are slaying for Novo Nordisk right now
Sales of Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy continue to soar, surpassing Wall Street expectations. The Danish pharma giant posted its third-quarter earnings report early Tuesday morning and boasted sales figures blowing past analysts’ projections.
Ever since their rise in popularity as weight loss drugs, there’s been a slew of reports on the potential adverse health ...
Novo Nordisk disclosed it knows of 10 deaths and 100 hospitalizations from people taking compounded copies of its weight loss ...
On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...
Westend61/Getty Images The use of GLP-1 medications such as semaglutide — more widely known under the brand names of Ozempic ...
People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss ...
GLP-1 agonist Wegovy (semaglutide) brought in DKK 17.3 billion ($2.49 billion) in the period, restoring earlier levels of ...
Our list of online Wegovy providers includes reputable brands with licensed healthcare providers who can support you on ...
Europe's most valuable company has invested billions in Kalundborg on Denmark's coast - but it has many problems.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback